The detailed substrate specificity of the UDP-GalNAc: sialylparagloboside N-acetylgalactosaminyltransferase to form the Sd(a +) blood group active carbohydrate determinant GalNAcfll-4(NeuAca2-3)Gal was studied using a membrane fraction prepared from human gastric fundic mucosa. Various sialosylated oligosaccharides and gangliosides were examined as acceptor substrates. Oligosaccharide substrates were fluorescence-labelled with 2-aminopyridine, and the transferase activity was quantified by h.p.l.c. using a reversed-phase column. The structures of the products were determined by glycosidase degradation and proton n.m.r. 3'-Sialyl-lactose (II3NeuAcLac), 3'-sialyl-lactotetraose (IV3NeuAcLc4), and 3'-sialyl-lactoneotetraose (IV3NeuAcnLc4) were good substrates for the /J1-4GalNAc transferase in gastric fundic mucosa, but 6'-sialyl-lactoneotetraose (IV6NeuAcnLc4) or 6'-sialyl-lactose (II6NeuAcLac) were not.
INTRODUCTION
Previously we have reported the presence of a sialylpentaosylceramide, localized specifically in human gastric fundic mucosa by using the anti-GM2 monoclonal antibody [1] . (The nomenclature used for glycolipids aind oligosaccharides is that of the system of Svennerholm [2] or the IUPAC-IUB [3] ). This glycolipid, temporally named NGM-1, was commonly found in the stomach of Japanese people, and was characterized as GalNAc,81-4(NeuAca2-3)Galfl14GlcNAc,l8-3Galfll-4Glc-Cer which shares the same terminal epitope as the GM2 ganglioside. We also found that the activity of UDP-GalNAc: sialylparagloboside ,f1-4GalNAc N-acetylgalactosaminyltransferase (NGM-l synthase) was high in the fundic mucosa, while the activity of UDPGalNAc: GM3 f1-4GalNAc N-acetylgalactosaminyltransferase (GM2 synthase) was very low. In contrast, an increased GM2 synthase activity was found in gastric cancer cell lines and gastric cancer tissue, and the activity of NGM-1 synthase was absent in pyloric-mucosa and gastric cancer [4] .
On the other hand, the carbohydrate moiety of NGM-l was shown to be identical to an immunodominant ganglioside of a rare blood group called Cad or Sd(a + + ) [5] . The incidence of Cad/Sd(a+ +) individuals, whose erythrocytes are rich in the NGM-1 glycolipid, is extremely low (reviewed in [6] ), and estimated as 0.03 % in the Japanese race [7] . In contrast, the antigen carrying GalNAcfll-4(NeuAca2-3)Gal as the terminal structure, probably on a glycoprotein, is widely distributed in mammalian tissues [8] , and is specified as Sd(a +) to distinguish it from Cad/Sd(a + +). In human tissues, this carbohydrate determinant has been reported to be present in the urine, kidney and colon iniore than 9f% of the Cacagian population [8, 9] , and the fll-4GalNAc transferase involved in the synthesis of this carbohydrate determinant has been detected in the kidney, serum and colon [7, 10, 12] . Studies on the fll-4GalNAc transferase in the stomach, however, have not been reported. We found the NGM-1 synthase to be a glycolipid synthase that is functionally different from the Sda antigen synthase which is considered to be responsible for producing soluble antigen. Besides Sd" antigens, glycolipids with the same terminal structure, GalNAcfll-4-(NeuAcac2-3)Gal, as NGM-1, GalNAc-GD1a and GalNAc-GMlb, have been detected in neural tissue [13, 14] . These studies on the ,81-4GalNAc transferase activity synthesizing GalNAc,l-4(NeuAca2-3)Gal prompted our investigation into the substrate specificity of the NGM-1 synthase in the human stomach.
In the present paper we describe a membrane fraction of the gastric fundic mucosa which was able to transfer GalNAc to an oligosaccharide acceptor, as well as sialylparagloboside. The detailed substrate specificity of the ,f1-4GalNAc transferase that produces GalNAcfl1-4(NeuAca2-3)Gal in human gastric fundic mucosa was determined using a panel of oligosaccharides and glycolipids of well-defined structure. Furthermore, we found that the activity of /?1-4GalNAc transferase towards sialosyloligosaccharides was localized in fundic mucosa as well as that to sialylparagloboside.
MATERIALS AND METHODS Tissue
An intact mucosal layer from the greater curvature of the gastric body (fundic area) was obtained from a surgically resected stomach from a patient treated for gastric cancer in the National Medical Center Hospital (Tokyo, Japan). After rinsing the tissue in cold phosphate-buffered saline (0.15 M-NaCl, 8 mM-Na2HPO4, 1.5 mM-KH2PO4, 2.7 mM-KCI, pH 7.2), it was minced, homogenized with a glass micro-homogenizer (Radnoti Glass, Monrovia, CA, U.S.A.) in 3 vol. of homogenizing buffer containing 250 mM-sucrose and 10 mM-Tris/HCl, pH 7.4, and centrifuged at 900 g for 10 min. In preparing the membrane fraction, the 900 g supernatant was centrifuged at 3000 g for 10 min, and the resulting supernatant was centrifu-ged at 100000g for 1 h. The pellet was suspend-ed in a homogenizing buffer. The biopsy samples were obtained from patients who had had an endoscopic examination of the stomach (Osaka Medical School Hospital) and had been found to have lesions requiring a histological examination. Each specimen was divided into two parts, one for histological examination and the other for assay of glycosyltransferase activity. In the latter case, samples were homogenized with a glass microhomogenizer in 100 #1 of homogenizing buffer, and the supernatant obtained after centrifugation with a microcentrifuge Capsule HF 120 (TOMY, Tokyo, Japan) was used for the assay. The protein concentration was determined by a Bio-Rad protein assay kit using BSA as a standard.
Glycolipids and oligosaccharides GM3 and sialylparagloboside were purified from human erythrocytes, GM2 and GDla from calf brain, and NGM-l from human gastric mucosa, and they were used as substrates or reference standards. GMlb was a gift from Dr. Hirabayashi (The Riken Institute of Physical and Chemical Research, Wako, Japan). 3'-Sialyl-lactose (II3NeuAcLac), 3'-sialyl-lactoneotetraose (IV3NeuAcnLc4), GalNAc-sialyl-lactose (II4GalNAc-II3NeuAcLac), and GalNAc-3'-sialyl-lactoneotetraose (IV4GalNAcIV3NeuAcnLc4) were prepared from GM3, sialylparagloboside, GM2 and NGM-1 respectively by treatment with endoglycoceramidase provided by Dr. M. Ito (Mitsubishi Kasei Institute of Life Sciences, Machida, Japan). 6'-Sialyl-lactose (IV8-NeuAcLac), 6 '-sialyl-lactoneotetraose (IV6NeuAcnLc4), and 3'-sialyl-lactotetraose (IV3NeuAcLc4) were purchased from Biocarb (Lund, Sweden). Lactoneotetraose (nLc4) and lactotetraose (Lc4) were prepared by incubation of 3'-sialyl-lactoneotetraose and 3'-sialyl-lactotetraose respectively in 1 % acetic acid at 100°C for I h.
Measurement of the glycosyltransferase activity using fluorescence-labelled oligosaccharide as substrate The assay was done following the modified method described by Taniguchi et al. [15] . Oligosaccharides were fluorescencelabelled with 2-aminopyridine according to the method described by Hase et al. [16] . The assay solution had the following final concentration in a total volume of 0.05 ml: 0.1 M-cacodylate buffer (pH 7.5), 0.01 M-MnCl2, 0.45 % Triton X-100, 0.01 M-UDP-GalNAc, 0.08 mM-pyridylaminated oligosaccharide (oligosaccharide-PA) as theacceptor substrate, and 50 ,ug ofmembrane protein or 20 ,l of crude homogenate. After incubation for 2 h, the reaction was stopped by boiling the samples for 2 min, and a 3,1u aliquot of the reaction mixture was analysed with an h.p.l.c. system equipped with a fluorescence monitor (Shimadzu RF-535T) using the reversed-phase column (TOSO TSK-Gel ODS-80TM, 0.45 cm x 25 cm) kept at 50°C. Ammonium acetate buffer (20 mM; pH 4.0) was used at a flow rate of I ml/min for a mobile isocratic phase. The reaction product was identified with the reference of the assay solution incubated in the absence of UDP-GalNAc. The amount of product was quantified by the fluorescence intensity calculated with a Shimadzu CR4-A Chromatopac using pyridylaminated lactose as a standard.
Structural identification of the oligosaccharide product by enzymic degradation
The reaction product separated from the substrate by h.p.l.c. was first incubated with 0.3 unit of N-acetylneuraminidase/ml from Anthrobacter (Nakarai, Kyoto, Japan) in 10 mMammonium acetate buffer (pH 4.6) for 24 h at 37 'C. Then Nacetylhexosaminidase from Jack bean (Sigma) was added to the reaction mixture to give a final concentration of 1.25 units/ml, and subsequently incubated for 24 h at 37 'C. Aliquots of the reaction mixture, after treatment with each enzyme, were analysed by h.p.l.c. as described above.
Structural identification of the oligosaccharide product by 'H n.m.r.
The pooled product (approx. 10 nmol) was purified by h.p.l.c. as mentioned above together with gel filtration with Toyopearl HW40 FINE (1 cm x 55 cm) in 10 mM-ammonium acetate buffer (pH 6.0), the eluate being monitored for fluorescence intensity.
The product was lyophilized and dissolved in 99.96% 'H2O (MSD Isotopes, Montreal, Canada) three times. 'H n.m.r. analysis at 400 MHz was performed at 30 'C in 2H O with a JNM-GX400 FT n.m.r. spectrometer in the Fourier-transform mode.
Measurement of the glycosyltransferase activity using glycolipid as substrate
The assay was performed using the optimized conditions described previously [4] , with the exception that radiolabelled sugar nucleotide was used following the method described by Kawano et al. [17] . The standard assay, in a total volume of 0.05 ml, consisted of the following components (final concentrations): 0.1 M-cacodylate buffer (pH 7.5), 0.01 M-MnCl2, 0.18 % Triton X-100, 84 /M-UDP-[14C]GalNAc (Amersham, 60 mCi/mmol), 0.08 mm substrate glycolipid and 50 ,ug of membrane protein. After incubating the assay for 2 h at 37 'C, the reaction was stopped by adding 1 ml of chloroform/ methanol/water (30-:60:8 by vol.) and the mixture was applied on 1 ml of DEAE Sephadex A-25 column equilibrated with the same solvent. After eluting the column with 2 ml of chloroform/methanol/water (30:60:8 by vol.) followed by 3 ml of methanol, the ganglioside fraction was eluted in 6 ml of 40 mmammonium acetate in methanol. The radioactivity was determined in 10 ml of scintillation fluid using a liquid scintillation spectrometer (Packard 4530).
RESULTS
Activity of GalNAc transferase towards oligosaccharide-PA Fig. 1 shows the h.p.l.c. elution pattern of the assay mixture when 3'-sialyl-lactose-PA or 3'-sialyl-lactoneotetraose-PA were used as the substrates. Fig. 2 demonstrates the results of the enzyme degradation of the products formed from 3'-sialyllactose-PA, 3'-sialyl-lactoneotetraose-PA and 3'-sialyl-lacto- PA, and lactotetraose-PA respectively. These results support the suggestion that GalNAcf8l-4(NeuAca2-3)Gal was formed by the reaction with the membrane fraction from gastric fundic mucosa. The structure of the product was also confirmed by 'H n.m.r. of pooled material compared with sugar-PA prepared from authentic GM2 or NGM-1 by treatment with endoglycoceramidase. Fig. 3 shows that the spectra of the product oligosaccharides were identical to those of sugar-PA derived from standard glycolipids. It was demonstrated therefore that the membrane fraction of gastric mucosa transferred GalNAc from UDPGalNAc to the galactose residue of 3'-sialyl-lactose and 3'-sialyllactoneotetraose in a ,1-4 linkage, constructing the same carbohydrate moiety as GM2 and NGM-1 respectively.
Substrate specificity of the fll4GaINAc transferase in fundic mucosa Table 1 shows that the membrane fraction of the gastric fundic mucosa could transfer GalNAc to 3'-sialyl-lactose-PA, 3'-sialyllactotetraose-PA, and 3'-sialyl-lactoneotetraose-PA, but it could not transfer to 6'-sialyl-lactoneotetraose-PA or 6'-sialyl-lactose-PA. It was also capable of transferring GalNAc to sialylparagloboside but not to GM3, GMlb and GD1a.
Distribution of fll4GaINAc transferase in the human stomach Table 2 shows the 8l1-4GalNAc transferase activity in biopsy samples from gastric mucosa. The activity of the /?1-4GalNAc transfer to sialyl-lactoneotetraose-PA and sialyl-lactose-PA was very high in gastric fundic mucosa, but the activity in most specimens from pyloric mucosa, intestinal metaplasia and cancer tissue was below detectable levels, irrespective of histopathological findings.
DISCUSSION
The current results demonstrated that the gastric fundic mucosa possessed the GalNAc transferase activity necessary to produce the GalNAc8ll-4(NeuAca2-3)Gal terminal structure on both an oligosaccharide and a glycolipid. Previously, we reported that the GalNAc transferase in the gastric fundic mucosa transfers GalNAc to sialylparagloboside, but not to GM3. This property of the f1-4GalNAc transferase was reminiscent of the f1-4GalNAc transferase related to the Sd8 antigen. Takeya et al. detected the UDP-GalNAc: NeuAca2-3Galf,l-4GlcNAc /11-4GalNAc transferase in human blood plasma [7] . They showed that sialyl-lactose and sialylparagloboside were good acceptors, but GM3 was not. Piller et al. reported that the microsomal preparations from human kidney were capable of transferring GalNAc to N-linked carbohydrates, 0-linked carbohydrates and sialylparagloboside, but not to GM3 [10] . Malagolini et al. studied the UDP-GalNAc:NeuAca2-3Gal-+R ,1-4GalNAc transferase in the human colon (where R is the carbohydrate structure) and showed that the enzyme prefers NeuAca2-3Gal-+R to NeuAca2-6Gal-.R as the acceptor in the experiment using human transferrin that contains only NeuAca2-6Galfl-R units [12] . In this paper, gastric fundic mucosa was found to be able to transfer GalNAc to oligosaccharides, and the results using sugar-PAs as substrates clearly demonstrated that the transferase worked on both type-l chain and type-2 chains, but the NeuAc should be linked in an a2-3 linkage to terminal galactose. Thus, the substrate specificity of human gastric mucosal enzyme in this study was similar to these fll-4GalNAc transferases reported as Sd" antigen synthases. So, is the fl1-4GalNAc transferase in the human stomach identical to the Sd(a +) antigen synthase in the human colon and kidney? Although we do not have results to show the difference between enzyme molecules in these organs, the functional difference is clear; the enzyme in the human stomach is responsible for the expression of glycolipid, whereas the Sd8 synthase in the human kidney or colon is not involved in the glycolipid synthesis, apparently because the NGM-1 glycolipid is not expressed in these organs [4] . To fl1-4N-Acetylgalactosaminyltransferase in the human stomach in spite ofthe same terminal residue NeuAca2-3Gal. The presence of GalNAc-GMlb and GalNAc-GDla in neural tissue has been reported [16, 17] . As they have the same terminal structure as NGM-1 and GM2, they are detected by cross-reactivity with most anti-(GM2) monoclonal antibodies [4, [18] [19] [20] . The fi1-4GalNAc transferase in the stomach, however, recognized the difference between NeuAca2-3Gal,81-4(or 3)GlcNAc and NeuAca2-3Galfll-3GalNAc, probably because of the differences in the three-dimensional structure. The fl1-4GalNAc transferase involved in the synthesis of GalNAc-GMlb (and GalNAc-GDl,) and that involved in the synthesis of NGM-l are apparently different, although they produced the same linkage of three sugars in the non-reduced terminal structure. It is still not clear whether GM2 synthase, which is believed to be the same enzyme as GD2 synthase [21] , and GalNAc-GMlb synthase can be similarly categorized. Current results make it evident that the fl -4GalNAc transferase in the stomach is distinct from these ,G1-4GalNAc transferases involved in the synthesis of ganglio-series glycolipid found in neural tissue. In addition, the result that high transfer activity to 3'-sialyl-lactose-PA and low activity to GM3 suggested the strong inhibitory effect of the ceramide moiety in GM3 on the activity of f1-4GalNAc transferase in gastric fundic mucosa.
The fll-4GalNAc transferase activity reported here exhibited strict localization in fundic mucosa. No activity was found in non-fundic gastric mucosa and gastric cancer tissue. This location of the enzyme suggested that the sugar moiety produced by this enzyme is possibly related to the function of the fundic mucosa in secreting HCI and pepsinogen.
